-
-
-
-
FDA Approves Repotrectinib (Augtyro) for NTRK
FDA
The FDA granted accelerated approval to repotrectinib (Augtyro) for adults and children aged 12+ with NTRK fusion-positive tumors. The TRIDENT-1 trial showed a 58% ORR in TKI-na?ve patients and a 50% ORR in TKI-pretreated patients, highlighting its efficacy and potential.
-
FDA Approves Imetelstat for Low- to Intermediate-1 Risk MDS
FDA
On June 6, 2024, the FDA approved imetelstat (Rytelo) for adults with low- to intermediate-1 risk myelodysplastic syndromes (MDS) and transfusion-dependent anemia. The approval is based on significant trial results demonstrating RBC transfusion independence.
-
-
-
-
-
界首市|
九寨沟县|
肥西县|
黎川县|
白山市|
呼玛县|
SHOW|
邛崃市|
晋江市|
临夏县|
郁南县|
沂水县|
深泽县|
秭归县|
南和县|
武穴市|
阿瓦提县|
安化县|
读书|
社旗县|
淳化县|
绍兴市|
大足县|
阿拉尔市|
龙游县|
资源县|
岳普湖县|
孙吴县|
长沙县|
子长县|
珲春市|
龙游县|
金堂县|
长武县|
额敏县|
义乌市|
遂溪县|
乃东县|
策勒县|
义乌市|
林甸县|